Just a few gene variants are responsible for most of the higher prostate cancer risk in men of African descent—removing these few variants makes the risk gap between populations disappear.
Scientific Claim
A small number of prostate cancer susceptibility loci—specifically rs9623117, rs6983267, rs10896449, rs10993994, and rs817826—account for the majority of genetic risk differences between African and non-African populations, with the combined effect of the top six SNPs explaining nearly all observed disparity.
Original Statement
“A small number of loci appear to drive elevated CaP risks in men of African descent including rs9623117, rs6983267, rs10896449, rs10993994, and rs817826... Continental differences in CaP risk disappear if the six SNPs that contribute the most to elevated CaP risk in African men are ignored (i.e. the sum of 62 remaining GDC scores is close to zero: 0.0099).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim is based on computational GDC calculations and bootstrap validation. The authors correctly avoid causal language and use 'drive' in the context of contribution to disparity, which is appropriate for association-based modeling.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Case-Control StudyLevel 3aWhether these five SNPs are independently associated with prostate cancer diagnosis and aggressiveness in men of African descent after adjusting for other genetic and environmental factors.
Whether these five SNPs are independently associated with prostate cancer diagnosis and aggressiveness in men of African descent after adjusting for other genetic and environmental factors.
What This Would Prove
Whether these five SNPs are independently associated with prostate cancer diagnosis and aggressiveness in men of African descent after adjusting for other genetic and environmental factors.
Ideal Study Design
A multi-center case-control study of 8,000 men of African descent (4,000 with biopsy-proven prostate cancer, 4,000 controls), genotyped for rs9623117, rs6983267, rs10896449, rs10993994, rs817826, and 100 other SNPs, with logistic regression modeling to isolate individual SNP effects on cancer risk and Gleason score.
Limitation: Cannot prove these SNPs are causal—only that they are associated.
Prospective Cohort StudyLevel 2aWhether a polygenic risk score based only on these six SNPs predicts prostate cancer incidence as accurately as a score based on all 68 SNPs in African descent populations.
Whether a polygenic risk score based only on these six SNPs predicts prostate cancer incidence as accurately as a score based on all 68 SNPs in African descent populations.
What This Would Prove
Whether a polygenic risk score based only on these six SNPs predicts prostate cancer incidence as accurately as a score based on all 68 SNPs in African descent populations.
Ideal Study Design
A prospective cohort of 15,000 African descent men aged 45–70, genotyped for all 68 SNPs, followed for 10 years; comparing AUC of prostate cancer prediction using a 6-SNP score vs. 68-SNP score, with calibration for age and ancestry.
Limitation: Does not establish biological mechanism; only tests predictive utility.
Systematic Review & Meta-AnalysisLevel 1aWhether these six SNPs consistently show the largest effect sizes and allele frequency differences across all published GWAS of prostate cancer in diverse populations.
Whether these six SNPs consistently show the largest effect sizes and allele frequency differences across all published GWAS of prostate cancer in diverse populations.
What This Would Prove
Whether these six SNPs consistently show the largest effect sizes and allele frequency differences across all published GWAS of prostate cancer in diverse populations.
Ideal Study Design
A meta-analysis of 25+ GWAS studies (>200,000 men total) comparing GDC values, ORs, and allele frequency differences for the 68 SNPs, focusing on whether the top six SNPs consistently rank highest in disparity metrics across ancestries.
Limitation: Relies on published data with potential bias toward European populations.
Functional Genomics AssayLevel 5Whether these six SNPs directly alter gene regulation in prostate tissue (e.g., enhancer activity, transcription factor binding).
Whether these six SNPs directly alter gene regulation in prostate tissue (e.g., enhancer activity, transcription factor binding).
What This Would Prove
Whether these six SNPs directly alter gene regulation in prostate tissue (e.g., enhancer activity, transcription factor binding).
Ideal Study Design
CRISPR-based editing of each of the six SNPs in human prostate organoids, followed by ATAC-seq, ChIP-seq, and RNA-seq to identify changes in chromatin accessibility, enhancer-promoter looping, and gene expression of nearby genes (e.g., TNRC6B, MYC, MSMB).
Limitation: Does not reflect population-level evolutionary dynamics or in vivo tumor microenvironment.
Randomized Controlled TrialLevel 1bWhether targeting these six SNPs with gene editing (e.g., CRISPR) reduces prostate cancer risk in high-risk individuals.
Whether targeting these six SNPs with gene editing (e.g., CRISPR) reduces prostate cancer risk in high-risk individuals.
What This Would Prove
Whether targeting these six SNPs with gene editing (e.g., CRISPR) reduces prostate cancer risk in high-risk individuals.
Ideal Study Design
A phase I trial of 30 men with high GRS (>95th percentile) and germline risk alleles at these six loci, receiving in vivo CRISPR-based allele correction in prostate tissue (if feasible), with PSA and biopsy outcomes monitored over 5 years.
Limitation: Currently not ethically or technically feasible for germline risk SNPs; highly speculative.
Evidence from Studies
Supporting (1)
Genetic Hitchhiking and Population Bottlenecks Contribute to Prostate Cancer Disparities in Men of African Descent.
Scientists found that a few specific gene changes are much more common in men of African descent and help explain why they’re more likely to get prostate cancer than others. These same gene changes are exactly the ones mentioned in the claim, so the study backs it up.